CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU (09/13/88)
Attached is the Table of Contents and articles of interest from the
NIH Guide to Grants and Contracts 7/29/88.
Jim Cassatt
--------------------------------------------------------------------
Vol. 17, No. 24, July 29, 1988
NOTICES
REVISED BOOKLET - NIH EXTRAMURAL PROGRAMS ..................(84/105)........ 1
National Institutes of Health
Index: NIH EXTRAMURAL PROGRAMS
MEETING - IRBs AT THE CROSSROADS: EXPANDING ROLES AND
EXPANDED PROBLEMS ..........................................(108/158)....... 1
Public Responsibility in Medicine and Research
Index: PUBLIC RESPONSIBILITY IN MEDICINE AND RESEARCH
NATIONAL RESEARCH SERVICE AWARD (NRSA) STIPEND INCREASE ....(161/203)....... 2
Public Health Service
Index: PUBLIC HEALTH SERVICE
DATED ANNOUNCEMENTS (RFPs AND RFAs)
SUPPORT SERVICES FOR EXPOSURE METHODS FOR PESTICIDES (RFP) ..(209/246)...... 2
National Cancer Institute
Index: CANCER
TRANSFUSION TRIAL TO PREVENT PLATELET ALLOIMMUNIZATION (RFA) ..(249/279)........
National Heart, Lung, and Blood Institute
Index: HEART, LUNG, AND BLOOD
MOLECULAR AND CELLULAR BIOLOGY OF CARDIAC INTERSTITIUM (RFA) ..(282/356).... 3
National Heart, Lung, and Blood Institute (888/1256)
Index: HEART, LUNG, AND BLOOD
ONGOING PROGRAM ANNOUNCEMENTS
ROLE OF MARKET FORCES IN THE DELIVERY OF HEALTH CARE (PA) .....(362/567).... 4
National Center for Health Services Research and Health Care
Technology Assessment
Index: HEALTH SERVICES RESEARCH
STUDIES OF THE PATHOPHYSIOLOGY OF NEUTROPENIAS AND THE MECHANISMS
OF ACTION OF COLONY STIMULATING FACTORS (PA) ..................(570/712).... 7
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
PATHOPHYSIOLOGICAL MECHANISMS OF ENTEROPATHOGENIC VIRUSES (PA) ..(721/838).. 9
National Institute of Allergy and Infectious Diseases
Index: ALLERGY AND INFECTIOUS DISEASES
NOTICES
REVISED BOOKLET - NIH EXTRAMURAL PROGRAMS
P.T. 34, 44; K.W. 0710030, 0720005
National Institutes of Health
The National Institutes of Health (NIH) has revised the NIH Extramural
Programs Booklet, Funding for Research and Research Training, May 1988, (NIH
Publication No. 88-33). This publication is a compendium of the scientific
programs of the NIH components that award grants, cooperative agreements, and
contracts. It indicates current areas of research emphasis, highlights the
special interests of each awarding component, and identifies specific NIH
offices that may be contacted for further information about particular
programs, policies, and procedures. Institutional officials and investigators
may obtain copies of this booklet by writing to:
Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, Maryland 20892
Telephone: (301) 496-7441
MEETING - IRBs AT THE CROSSROADS: EXPANDING ROLES AND EXPANDED PROBLEMS
P.T. 42; K.W. 1014002, 1014003, 0783005
Public Responsibility in Medicine and Research
Public Responsibility in Medicine and Research (PRIM&R), a national
organization concerned with ethical issues in research and medicine, is
sponsoring a meeting entitled, "IRBs at the Crossroads: Expanding Roles and
Expanded Problems." The meeting will be held on October 27-28, 1988, at the
Boston Park Plaza Hotel, Boston, Massachusetts.
The conference will look at the Federal Regulations on Research with Human
Subjects, and will reassess their breadth as of their tenth anniversary
approaches. Other issues to be examined at this meeting will include the
problems of fraud and misconduct in medical research; the conduct of clinical
trials in general, and subject payment for research drugs and devices in
particular; IRB review of innovative therapies, including sequencing the
genome, genetic testing and genetic research; input by pharmaceutical
companies into the IRB review process; researcher responsibility in
determining appropriate uses of confidentially acquired research data,
including those derived from HIV-related projects; the use of cell lines and
tissues, including fetal tissues; research with the elderly; the IRB's role in
educating investigators and other institutional staff; reviewing research
involving biohazards, and reviewing AIDS research - including vaccine
development, etc.
As in the past, the conference will include two specially designed educational
series, one for committee administrators, and the second for new IRB members.
This series serves as a basic orientation course for any new member, chair, or
administrator.
The meeting will consist of both plenary sessions and workshops, and will have
a faculty of over thirty distinguished experts from the fields of IRB
operation and administration, research and clinical practice, the Federal
Government, the legal profession, and practicing ethicists.
On October 26, 1988, Applied Research Ethics National Association (ARENA) will
host its third annual meeting, also at the Park Plaza Hotel in Boston. This
meeting will be held from 9 a.m. to 5 p.m., and will include a variety of
speakers and workshops addressing issues pertinent to both IRB and IACUC
administrators.
For complete programs or further information please contact:
PRIM&R
132 Boylston Street
4th Floor
Boston, Massachusetts 02116
Telephone: (617) 423-4112 or
(617) 423-1099
Vol. 17, No. 24, July 29, 1988 - Page 1
NATIONAL RESEARCH SERVICE AWARD (NRSA) STIPEND INCREASE
P.T. 22, 44; K.W. 1014002, 0720005
Public Health Service
Effective October 1, 1988, the annual stipend levels for all individuals
receiving support through awards made under the National Research Service
Award (NRSA) Act, P.L. 93-348 as amended under P.L. 99-158, will be as
follows:
Predoctoral Stipend
All Years Current As of October
1, 1988
---- $ 6,552 $ 8,500
Postdoctoral Stipend
Years of
Relevant Present
Experience Stipend As of October
1, 1988
0 $15,996 $17,000
1 17,004 18,000
2 21,996 25,000
3 23,004 26,250
4 24,000 27,500
5 26,004 28,750
6 27,996 30,000
7 or more 30,000 31,500
Stipend level adjustments can be made only on the award date of the fellowship
or the appointment date of the trainee. These stipend levels are effective
only for awards made beginning with FY 1989 funds; no retroactive adjustments
or supplementation of stipends with NRSA funds for awards made prior to
October 1, l988, or with funds from FY 1988 is permitted.
The new stipend levels are to be used in the preparation of future NRSA
institutional training and individual fellowship applications. They will be
administratively applied to all applications now in the review process.
DATED ANNOUNCEMENTS (RFPs AND RFAs)
SUPPORT SERVICES FOR EXPOSURE METHODS FOR PESTICIDES
RFP AVAILABLE: NCI-CP-95602-25
P.T. 34; K.W. 0725005, 1007009, 0785055, 0404021
National Cancer Institute
The Environmental Epidemiology Branch (EEB) of the Epidemiology and
Biostatistics Program (EBP) of the Division of Cancer Etiology (DCE) of the
National Cancer Institute (NCI) is seeking a Contractor who will support the
EEB by conducting epidemiological and natural history studies of the
individuals who use pesticides, specifically farmers and their next-of-kin.
Components of this project include: developing questionnaires to obtain
detailed information on pesticide use; conducting interviews and reinterviews
of subjects regarding pesticide use, to assess intra-individual reliability;
conducting interview of subjects and surrogates to compare quality of their
responses, comparing subject's recall regarding past pesticide use with
purchase records of the subjects and their pesticide suppliers; obtaining air,
wipe, blood and urine samples to obtain measures of pesticide exposure (only
collection and transportation of the samples will be handled under this
contract: analyses will be the responsibility of the NCI); and assembling a
panel of pesticide experts to obtain their assessment of the validity of
subject responses. It is anticipated that an incrementally funded,
cost-reimbursement, completion type contract will be awarded for a two-year
period. The anticipated issue date of this RFP is on or about July 22, 1988,
with responses due 30 days from the actual date of RFP issuance.
Copies of the RFP may be obtained by submitting a written request to:
MOLECULAR AND CELLULAR BIOLOGY OF CARDIAC INTERSTITIUM
RFA AVAILABLE: 88-HL-19-H
P.T. 34; K.W. 0705015, 1002004, 1002008, 0765035
National Heart, Lung, and Blood Institute
Application Receipt Date: January 16, 1989
BACKGROUND
Congestive heart failure (CHF) afflicts approximately 2.3 million Americans
and has become the most frequently specified DRG (diagnostic related groups).
CHF has a variety of etiologies all of which result in loss of cardiac
mechanical function. While the role of hypertrophy, necrosis, and altered
function of heart muscle cells are the subject of considerable research, the
role of changes in the cardiac interstitium has received relatively little
attention. Yet, morphologists have shown that profound structural changes
occur in the interstitium as a result of ischemia, hypertrophy, or viral
infection. In the past, these changes have generally been regarded as passive
phenomena and reparative processes. Accumulating evidence now suggests that
remodeling of the connective tissue framework of the heart may contribute to
the disease process and the appearance of heart failure. A major component of
the connective tissue framework of the heart is fibrillar collagen which
appears to be secreted by cardiac fibroblasts residing in the interstitium.
OBJECTIVES AND SCOPE
The overall goal is to encourage research focused on the molecular and
cellular biology of the cardiac interstitium and on mechanisms involved in the
initiation and control of changes which occur as a result of physiologic and
pathologic stimuli. Examples of appropriate projects are: expression and
regulation of cardiac fibroblast collagen genes and collagenase genes;
interactions between fibroblasts and other cells and components of the cardiac
interstitium; and factors involved in the migration and proliferation of
cardiac fibroblasts.
Vol. 17, No. 24, July 29, 1988 - Page 3
MECHANISM OF SUPPORT
The support mechanism for this program will be the traditional, individual
research grant. All current policies and requirements that govern the
research grant programs of the National Institutes of Health will apply to
grants awarded under this RFA. Awards will be made to foreign institutions
only for research of very unusual merit, need, and promise, and in accordance
with Public Health Service policy governing such awards.
The financial plans for fiscal year 1989 include $1,500,000 for the total
costs of this program, award of grants pursuant to this RFA is contingent upon
receipt of funds for this purpose. It is anticipated that up to ten grants
will be awarded under this program. The specific amount to be funded will,
however, depend on the merit and scope of the applications received and on the
availability of funds.
REVIEW PROCEDURES
All applications submitted in response to this RFA will be evaluated for
scientific and technical merit by an initial review group, which will be
convened for this purpose, by the Division of Extramural Affairs, NHLBI.
METHOD OF APPLYING
Potential applicants should write or phone the individual listed below for the
full RFA document, which includes instructions for the submission of
applications:
Constance Weinstein, Ph.D.
Cardiac Diseases Branch
Division of Heart and Vascular Diseases
National Heart, Lung and Blood Institute, NIH
Federal Building, Room 3C06
7550 Wisconsin Avenue
Bethesda, Maryland 20892
Telephone: (301) 496-1081
PATHOPHYSIOLOGICAL MECHANISMS OF ENTEROPATHOGENIC VIRUSES
P.T. 34; K.W. 0765035, 1002045, 0785055
National Institute of Allergy and Infectious Diseases
Application Receipt Dates: February 1, June 1, and October 1
I. Background
The pathogenesis and epidemiology of disease caused by the interaction of
enteropathogenic viruses with the various cells of the intestine has not been
elucidated for most viruses. Yet throughout the world, viral gastroenteritis
afflicts millions of individuals of all ages every year. In the U.S. and
other developed countries where bacterial infections of the gastrointestinal
tract are less prevalent, the viral agents are a special problem. Where
studied, they can cause severe life-threatening diarrhea, vomiting and
dehydration in infants, and a diarrhea and vomiting syndrome in older children
and adults that interferes with work, school and play. Although progress has
been achieved with the development of some rotavirus vaccine candidates, more
rapid progress is anticipated when the pathogenesis and mechanisms of immunity
have been defined for all groups of enteropathogenic viruses.
II. Research Objectives and Scope
The National Institute of Allergy and Infectious Diseases (NIAID) invites
applications for research grants on viral infections of the bowel as part of
its continuing program in support of research in infectious enteric diseases.
Applications should focus on the role of any one or combination of the
following human enteropathogenic viruses: type A and type B rotavirus,
Norwalk virus and 27nm small round viruses, astrovirus, calicivirus,
coronavirus, and enteric adenovirus. Other unclassified viral-like agents are
not to be excluded. Experimental models of animal enteric viruses are also
encouraged.
More specifically, information is sought on viral receptors, intracellular
virus replication, viral effects on enterocyte metabolism, mechanisms of the
secretory diarrhea, host immune responses (short and long-term), and
epidemiological studies that clarify the transmission parameters. Proposed
investigator-initiated research can explore the mechanisms of enteric virus
pathogenesis in vitro, in animal models, or in man. Diagnostic reagents and
assays for investigations of many of the human enteric viruses will soon be
available from the CDC under an Interagency Agreement sponsored by the NIAID.
Recommendations for this program announcement originated in an NIAID/NIDDK
sponsored conference entitled, "Prospects for Effective Non-Antimicrobial
Antidiarrheal Agents" held at the NIH, May 8-9, 1986. Advances in molecular
virology, recent cultivation and diagnosis of several human enteric viruses,
and development of useful animal models provide a scientific basis for this
initiative.
III. Review Procedures
Applications in response to this announcement will be reviewed on a
nation-wide basis in competition with other applications and in accordance
with the usual National Institutes of Health peer review procedures. The
initial review for scientific and technical merit will be by an appropriate
study section of the Division of Research Grants, NIH; secondary review will
be by the National Institute of Allergy and Infectious Diseases Advisory
Council. Funding decisions will be based upon relative scientific merit,
program relevance, and the availability of appropriated funds.
IV. Mechanisms of Support (Listed by Grant Code)
R01 Research Project (Traditional) R29 First Independent Research Support and
Transition (FIRST) Award R43 Small Business Innovation Research Grants (SBIR)
F32 Postdoctoral Individual National Research Service Award K04 Modified
Research Career Development Award K08 Clinical Investigator Award K11
Physician Scientist Award (Individual) N43 Small Business Innovation Research
- Phase I (Contract) P01 Research Program Projects
V. Application Procedure
Applications will be accepted on an indefinite basis in accordance with the
receipt, Initial Review Group, National Advisory Council, and earliest
possible beginning dates specified in the application kit. On the first
(face) page, item 2, of the application, the "Yes" should be checked and the
phrase "RESPONSE TO NIAID ANNOUNCEMENT ON THE PATHOPHYSIOLOGICAL MECHANISMS OF
ENTEROPATHOGENIC VIRUSES" should be typed in the space provided.
Vol. 17, No. 24, July 29, 1988 - Page 9
The original and six copies of the application should be sent or delivered to:
Applications Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, Maryland 20892**
VI. Staff Contact
For further information concerning this announcement and the mechanisms of
support for research, investigators are encouraged to contact:
George Curlin, M.D.
Microbiology and Infectious Diseases Program
NIAID, NIH
Westwood Building, Room 749
Bethesda, Maryland 20892
Telephone: (301) 496-8362
or
William P. Allen, Ph.D., Chief
Bacteriology and Virology Branch
MIDP, NIAID, NIH
Westwood Building, Room 736
Bethesda, Maryland 20892
Telephone: (301) 496-7728
Applications oriented towards epidemiology and clinical studies should be
mailed to Dr. Curlin, and those oriented towards basic research should be
mailed to Dr. Allen.
Support is authorized by the Public Health Service Act, Public Law 78-410, as
amended. The Catalog of Federal Domestic Assistance citation is Sec. 13.856,
Microbiology and Infectious Diseases Research. Awards will be administered
under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR